Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Operating Leases (2022 - 2025)

Rapid Micro Biosystems' Operating Leases history spans 3 years, with the latest figure at $5.0 million for Q4 2024.

  • For Q4 2024, Operating Leases fell 20.28% year-over-year to $5.0 million; the TTM value through Dec 2024 reached $5.0 million, down 20.28%, while the annual FY2024 figure was $5.0 million, 20.28% down from the prior year.
  • Operating Leases for Q4 2024 was $5.0 million at Rapid Micro Biosystems, down from $5.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $7.5 million in Q3 2022 and bottomed at $1.3 million in Q1 2022.
  • The 3-year median for Operating Leases is $5.7 million (2023), against an average of $5.4 million.
  • The largest annual shift saw Operating Leases decreased 13.72% in 2023 before it dropped 20.28% in 2024.
  • A 3-year view of Operating Leases shows it stood at $7.2 million in 2022, then fell by 13.72% to $6.2 million in 2023, then fell by 20.28% to $5.0 million in 2024.
  • Per Business Quant, the three most recent readings for RPID's Operating Leases are $5.0 million (Q4 2024), $5.3 million (Q3 2024), and $6.2 million (Q4 2023).